Publication | Open Access
Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier.
240
Citations
25
References
1994
Year
NeuropeptidesPain MedicineMolecular PainGlycopeptide Enkephalin AnaloguesPharmacotherapyExperimental PharmacologyGastrointestinal Peptide HormoneMolecular PharmacologyAnesthesiaPain ManagementAnesthetic PharmacologyHealth SciencesBlood-brain BarrierNeuropharmacologyPeptide MessagePharmacological AgentPharmacologyPain ResearchPhysiologyNeuropeptide ReceptorMouse BrainMost PeptidesMedicineDrug DiscoveryAnesthesiology
Most peptides have not proved useful as neuroactive drugs because they are blocked by the blood-brain barrier and do not reach their receptors within the brain. Intraperitoneally administered L-serinyl beta-D-glucoside analogues of [Met5]enkephalin (glycopeptides) have been shown to be transported across the blood-brain barrier to bind with targeted mu- and delta-opioid receptors in the mouse brain. The opioid nature of the binding has been demonstrated with intracerebroventricularly administered naloxone. Paradoxically, glucosylation decreases the lipophilicity of the peptides while promoting transport across the lipophilic endothelial layer. It is suggested that glucose transporter GLUT-1 is responsible for the transport of the peptide message. Profound and long-lasting analgesia has been observed in mice (tail-flick and hot-plate assays) with two of the glycopeptide analogues when administered intraperitoneally.
| Year | Citations | |
|---|---|---|
Page 1
Page 1